What is it about?
Changes in urinary protein excretion have been shown to predict the risk of end-stage kidney disease. We demonstrate that early changes in urinary protein excretion during treatment with the drug atrasentan did not predict the efficacy of atrasentan in reducing the risk of end-stage kidney disease.
Featured Image
Read the Original
This page is a summary of: Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial, Journal of the American Society of Nephrology, September 2021, American Society of Nephrology,
DOI: 10.1681/asn.2021030391.
You can read the full text:
Contributors
Be the first to contribute to this page
